Alkem Labs signs licensing agreement with Sonnet BioTherapeutics to develop diabetic neuropathy treatment

October 10, 2024
Uncategorized

Under the licensing agreement, Alkem will carry out the clinical development of ‘SON-080’ in India with support from Sonnet and enable global and India regulatory filings.

Alkem Labs signs licensing agreement with Sonnet BioTherapeutics to develop diabetic neuropathy treatment

Leave a ReplyCancel Reply

Tata Motors shares are up 10% in one month; Here is another trigger for the stock

Trade Setup for June 2: Nifty struggles to move out of narrow range amidst rising trade tensions, RBI decision

Mahindra & Mahindra vehicle sales up 17% in May at 84,100 units

Stocks to Watch: Vodafone Idea, Apollo Hospitals, Coal India, Nykaa, IRB Infra and more

Market valuation of four of top-10 most valued firms jumps ₹1 lakh crore; LIC biggest gainer